Skin toxicity as a risk factor for major infections in breast cancer patients treated with docetaxel
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Nittby, Lena Tennvall
Madsen, Ebbe Lindegaard
MetadataShow full item record
CitationActa Oncol 2004, 43(2):190-5
AbstractDocetaxel-related skin toxicity, oral and gastrointestinal mucosal toxicity, and changes in blood cell counts were investigated as predictive factors for major infections in 143 women treated with 3-weekly docetaxel (100 mg/m2) as second-line therapy for metastatic breast cancer in a randomized trial. Each patient with a major infection (n = 37) was compared with two controls. Skin toxicity (odds ratio 2.97, 95% CI 1.37-6.47), oral mucositis (1.98, CI 1.30-3.04), and the leukocyte nadir (0.12, CI 0.02-0.51) were significantly associated with a major infection in a univariate logistic regression analysis. In a multivariate analysis, skin toxicity was the only independent factor predictive for grade 3 to 4 infection (2.75, CI 1.00-7.58). A major infection was diagnosed in 62% (8 out of 13) of the docetaxel cycles in severely (grade 4) leukopenic patients who had grade 2 to 4 skin toxicity. Major infections are common in leukopenic patients who develop docetaxel-associated skin toxicity, and leukopenic patients presenting with docetaxel-induced skin toxicity may be candidates for prophylactic anti-infection measures such as prophylactic therapy with hematopoietic growth factors.
DescriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Link field
- Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.
- Authors: Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, Bontenbal M, Awada A, Selleslags J, Van Vreckem A, Van Glabbeke M
- Issue date: 1997 Sep
- Activity and toxicity of docetaxel (Taxotere) in women with previously treated metastatic breast cancer.
- Authors: Shapiro JD, Millward MJ, Rischin D, Davison JD, Michael M, Francis PA, Ganju V, Toner GC
- Issue date: 1997 Feb
- Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
- Authors: Alba E, Martín M, Ramos M, Adrover E, Balil A, Jara C, Barnadas A, Fernández-Aramburo A, Sánchez-Rovira P, Amenedo M, Casado A, Spanish Breast Cancer Research Group.
- Issue date: 2004 Jul 1
- Phase I study of docetaxel administered by bi-weekly infusion to patients with metastatic breast cancer.
- Authors: Shin E, Ishitobi M, Hiraoia M, Kazumasa F, Hideyuki M, Nishisho I, Toshiro S, Yasunori H, Tosimasa T
- Issue date: 2000 Nov-Dec
- A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer.
- Authors: Ford HE, Yap YS, Miles DW, Makris A, Hall M, Miller L, Harries M, Smith IE, Johnston SR
- Issue date: 2006 Dec